Healthcare Insurance Options for Early Retirement – Part I

More and more people are retiring before age 65, which creates certain problems for healthcare insurance coverage. Most retirees can count on Medicare to pick up most of the tab for their retirement healthcare, but what if you’re too young to qualify?

Gail Marks Jarvis, writing for The Wall Street Journal, offers us a reality check. “For a couple, premiums for coverage can run from $1,700 to $2,200 a month depending on where they live, their age and the source of the insurance. And besides premiums, there are deductibles, copays and prescriptions and coinsurance costs—potentially adding thousands of dollars more in extra costs. The upshot: Leaving work just four years before starting Medicare at age 65 can easily drain $100,000 or more from retirement savings.”

What’s more, some insurance options have a limited local network and might not include preferred doctors or allow participants to see a specialist without a referral. And many don’t cover expenses incurred out of state unless it is an emergency, a potential deal breaker for a retiree who wants to spend winters in a warmer climate.

 It’s easy to think you’ll have the same quality healthcare insurance coverage after you retire, but such is often not the case. Planning is needed to address this important issue before your last day of work. What are some options to consider?

Options

  • Employer coverage
  • ACA coverage
  • Private coverage
  • Last resorts

Employer Coverage

The cheapest option for a couple is to stagger retirements and have one keep working so both can rely on a workplace plan until Medicare becomes an option at 65. Workplace plans tend to be subsidized, with the employer paying about 83% of the cost of coverage for the employee on average, according to the Kaiser Family Foundation. For family coverage, the employee must pick up an additional share of the expense.

But that approach isn’t always feasible if you’re single or if neither partner wants to delay retirement. So another way to stay on a workplace plan and stay retired is through so-called Cobra coverage, which allows workers at many companies the right to continue health benefits for as many as 18 months if they leave their job under certain circumstances such as voluntary or involuntary job loss, reduction in hours worked or other life events.

Cobra coverage will cost more than if you are employed, with many employers requiring such plan participants to pay full fare, plus a 2% administration fee. However, the Cobra option will allow you to keep your preferred doctors as you consider what to do next. The average Cobra premium for a family recently ran about $25,000 a year, including the 2% fee, according to the Kaiser Family Foundation. That compares with an average of $6,775 a year the employee was accustomed to paying through paycheck deductions.

ACA Coverage

While using Cobra may be a good stopgap, moving to insurance through the Affordable Care Act marketplace is usually far less expensive because most people qualify for subsidies thanks to recent regulatory changes by the Biden administration to guide more people onto the program. Even people with more than $200,000 in income qualify in some parts of the country, and income typically plunges after leaving a job.

The ACA program includes four tiers of coverage: platinum, gold, silver and bronze. The bronze plans have the lowest premiums, silver next, then gold and platinum. Financial planners sometimes say silver is the best value, but that isn’t always the case once all potential out-of-pocket costs are compared, says Chumbley Hogue. Subsidies can be examined with the Kaiser Health Insurance Marketplace Calculator.

 Nationally, the average 63-year-old couple with a $150,000 income would get a $13,689 subsidy to significantly reduce the $26,439 premium on a silver plan. Subsidies vary by location and income. A family of four with an income up to $45,000 wouldn’t have to pay a premium for a silver plan. In New York City, a 63-year-old couple with an income of $250,000 could qualify for a small subsidy to reduce their premium.

Beyond cost considerations, ACA plans are more user-friendly than other private options because they won’t disallow coverage based on pre-existing conditions and can’t deny coverage or boot policyholders if they become sick after buying the insurance. Still, retirees who choose this route aren’t home-free after paying premiums. The plans have deductibles and other requirements like copays and coinsurance for doctors, hospitals and prescriptions. Furthermore, you may not have access to the best doctors and hospitals who don’t participate in the ACA program.

(Note: More on options to consider next post.)

Early Cancer Detection – Part II

In Part I of this series, we learned that there is a new cancer screening test that has shown the ability to detect cancers earlier than possible before, which has led to more effective treatment. Roger Royse, a lawyer in California, had the test which detected early pancreatic cancer, which is usually detected late when it is routinely fatal. But because his cancer was detected early, he had successful treatment and is now cancer free.

Allysia Finley, writing in The Wall Street Journal, tells us this happy ending was only made possible, however, because Mr. Royse was willing to pay for the test out of his own pocket, because insurance wouldn’t pay for it. Which leads to the obvious question, why not?

The test is relatively expensive at $949, but this is cheap compared to other tests that are routinely done, like MRI scans, which usually cost thousands. The test, called Galleri, is produced by a company called Grail.

Grail’s test has a roughly 0.5% false-positive rate, meaning 1 in 200 patients who don’t have cancer will get a positive signal. Its positive predictive value is 43%, so that of every 100 patients with a positive signal, 43 actually have cancer. That may sound low, but the positive predictive value for some recommended cancer screenings is far lower. Fewer than 1 in 10 women with an abnormal finding on a mammogram are diagnosed with breast cancer.

Because Grail uses machine learning to detect DNA-methylation cancer linkages, the Grail test’s accuracy should improve as more tests and patient data are collected. Dr. Ofman says the company also aims to reduce the test’s cost by scaling up manufacturing and detecting cancers with less genetic sequencing.

But therein lies a chicken-and-egg problem. Patient access is limited by Galleri’s lack of Food and Drug Administration approval and insurance coverage. These could help reduce the test’s costs and improve its accuracy. But regulators may balk at approving the test, and insurers at covering it, until it becomes cheaper and more reliable.

Regulators classify Galleri as a lab-developed test. Such tests are overseen by the Centers for Medicare and Medicaid Services and can be prescribed without FDA approval. This regulatory pathway allows hospitals, research centers and startups to develop tests without running the FDA’s bureaucratic gantlet. Since diagnostic tests can’t injure patients, no safety review is necessary.

The FDA in October proposed regulating lab-developed tests as medical devices, which generally require agency approval. That could severely curtail patient access and slow test development since the FDA doesn’t have the personnel to evaluate the tens of thousands of lab-developed tests on the market. The rule’s public comment period closed on Dec. 4.

Finley says, “Requiring randomized controlled trials and FDA approval for multicancer early-detection tests could restrict access for years. Hundreds of thousands of patients would likely have to be enrolled in trials, some receiving the test with the others in a control group. They would have to be followed over many years to determine whether patients who received the test were diagnosed with specific cancers earlier than those in the control group and how much longer they lived as a result. Proving a statistically significant benefit could take a decade or longer.”

One alternative is to rely on real-world studies, which Grail is already doing. One study of patients 50 and older without signs of cancer showed that the test doubled the number of cancers detected. The FDA could also approve the test, and CMS could provide Medicare coverage, on the condition that providers collect patient data that can be used to analyze the benefits.

Dana Goldman, the University of Southern California’s dean of public policy, likes that idea: “There will be a lot of suffering if we have to wait 10 years for the tests to be approved.” Mr. Goldman has spent decades studying the economics of medical treatments. One recurring problem he has seen: “Epidemiologists are always getting cancer wrong,” he says. “Epidemiologists a decade ago said U.S. overtreats cancers. Well, no, the EU undertreats cancer.”

A 2012 study that he co-authored found that the higher U.S. spending on cancer care relative to Europe between 1983 and 1999 resulted in significantly higher survival rates for American patients than for those in Europe. By his study’s calculation, U.S. spending on cancer treatments during that period resulted in $556 billion in net benefits owing to reduced mortality.

He expects Galleri and other multicancer early-detection tests to reduce deaths and produce public-health and economic benefits that exceed their monetary costs. Cancers caught early are cheaper to treat—less likely to require a cocktail of expensive therapies, and in some cases removable without the need for chemotherapy.

Let’s hope this test is approved by private insurance and Medicare soon. We need all the early detection cancer screening tests we can get!

Early Cancer Detection – Part I

Cancer treatment has come a long way from where it was in 1975 when I entered medical school. But success is still mainly dependent upon early detection. With early detection, the cure rate for many cancers is exceedingly high. Therefore, who wouldn’t want to improve our ability to detect cancers early?

Allysia Finley, writing for The Wall Street Journal, tells us of the dramatic case of Roger Royse, who was diagnosed with pancreatic cancer in July, 2022. But unlike most people, Royse was diagnosed in Stage II, with limited disease, instead of Stage IV. The five-year relative survival rate for late-stage metastatic pancreatic cancer is 3% – which means that patients are 3% as likely to live five years after their diagnosis as other cancer-free individuals. But if pancreatic cancer is caught before it has spread to other organs, the survival rate is 44%.

The trouble is that this cancer is almost never caught early. There’s no routine screening for it, and symptoms don’t develop until it is advanced. Mr. Royse, 64, had no idea he was sick until he took a blood test called Galleri, produced by the Menlo Park, Calif., startup Grail. He had surgery and chemotherapy and is now cancer-free.

Early diagnosis is the best defense against most cancers, as President Biden noted when he announced his Cancer Moonshot initiative two years ago. But only a handful of cancers—of the breast, lung, colon and cervix—have screening tests recommended by the U.S. Preventive Services Task Force, an independent panel that evaluates medical screenings.

Many companies are developing blood tests that can detect cancer signals before symptoms occur, and Grail’s is the most advanced. A study found it can identify more than 50 types of cancer 52% of the time and the 12 deadliest cancers in Stages I through III 68% of the time.

Naturally, it’s expensive. The test costs $949 and isn’t covered by Medicare or most private insurance. Mr. Royse, a lawyer who works with Silicon Valley startups, paid out of pocket for the test and follow-up imaging to confirm his cancer. Most Americans can’t afford to do so, and some public-health experts think that’s just as well. They fret that widespread use of multicancer early-detection tests would cause healthcare spending to explode. Those fears have snarled Galleri and similar tests in a web of red tape.

Mr. Royse learned about Grail’s test in April 2022 and asked his physician about it. “He said it was unnecessary, and you don’t have symptoms,” Mr. Royse says. A second doctor also refused to prescribe it. So Mr. Royse visited Grail’s website, which referred him to a telemedicine provider who ordered a test. Another telemedicine doctor walked him through his results, which showed a cancer signal likely emanating from the pancreas, gallbladder, stomach or esophagus.

An MRI revealed a suspicious mass on his pancreas, which a biopsy confirmed was cancerous. Mr. Royse had three months of chemotherapy, surgery and another three months of chemotherapy, which ended last February. Because pancreatic cancer often recurs, he gets CT and MRI scans every three months. In addition, he has signed up for startup Natera’s Signatera customized blood test, which checks DNA specific to the patient’s cancer and can signal its return before signs are visible on the scans.

Grail’s test has a roughly 0.5% false-positive rate, meaning 1 in 200 patients who don’t have cancer will get a positive signal. Its positive predictive value is 43%, so that of every 100 patients with a positive signal, 43 actually have cancer. That may sound low, but the positive predictive value for some recommended cancer screenings is far lower. Fewer than 1 in 10 women with an abnormal finding on a mammogram are diagnosed with breast cancer. Yet all women over 40 are advised to get regular mammograms.

What is hampering the widespread use of this new form of cancer screening?

More on that next post.